Occult hepatitis B virus infection: A covert operation

Journal of Viral Hepatitis

Volumn 17, Issue 1, 2010, Pages 1-15

  Hollinger, F B ^a   Sood, G ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Blood donors; Chronic hepatitis; HBV; HCV; Occult hepatitis B

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; INTERFERON; LAMIVUDINE; RITUXIMAB; TELBIVUDINE; TENOFOVIR;

ACUTE HEPATITIS; BLOOD DONOR; CHRONIC LIVER DISEASE; DNA DETERMINATION; GENE AMPLIFICATION; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOPATHOGENESIS; INFECTION RISK; LIVER BIOPSY; LIVER FAILURE; PERIPHERAL BLOOD MONONUCLEAR CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; SENSITIVITY AND SPECIFICITY; VIRUS LOAD; VIRUS REPLICATION; VIRUS TRANSMISSION;

ALANINE TRANSAMINASE; DNA, VIRAL; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HUMANS;

EID: 72949091738     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2009.01245.x     Document Type: Review

References (117)

1. Raimondo G, Navarra G, Mondello S et al. Occult hepatitis B virus in liver tissue of individuals without hepatic disease. J Hepatol 2008 48 : 743 746.
2. Torbenson M, Thomas DL. Occult hepatitis B. Lancet Infect Dis 2002 2 : 479 486.
3. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001 135 : 759 768.
4. Zacharakis G, Koskinas J, Kotsiou S et al. Natural history of chronic hepatitis B virus infection in children of different ethnic origins: a cohort study with up to 12 years' follow-up in northern Greece. J Pediatr Gastroenterol Nutr 2007 44 : 84 91.
5. Villeneuve JP, Desrochers M, Infanterivard C et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994 106 : 1000 1005.
6. de Franchis R, Meucci G, Vecchi M et al. The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993 118 : 191 194. (Pubitemid 23034804)
7. Gigi E, Lalla T, Orphanou E, Sinakos E, Vrettou E, Raptopoulou-Gigi M. Long term follow-up of a large cohort of inactive HBsAg(+)HBeAg(-)anti-HBe(+) carriers in Greece. J Gastrointestin Liver Dis 2007 16 : 19 22.
8. Laras A, Koskinas J, Dimou E, Kostamena A, Hadziyannis SJ. Intrahepatic levels and replicative activity of covalently closed circular hepatitis B virus DNA in chronically infected patients. Hepatology 2006 44 : 694 702.
9. Werle-Lapostolle B, Bowden S, Locarnini S et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology 2004 126 : 1750 1758.
10. Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci USA 1996 93 : 4398 4402.
11. Ganem D. Assembly of hepadnaviral virions and subviral particles. Curr Top Microbiol Immunol 1991 168 : 61 83.
12. Cacciola I, Pollicino T, Squadrito G et al. Quantification of intrahepatic hepatitis B virus (HBV) DNA in patients with chronic HBV infection. Hepatology 2000 31 : 507 512.
13. Pollicino T, Raffa G, Costantino L et al. Molecular and functional analysis of occult hepatitis B virus isolates from patients with hepatocellular carcinoma. Hepatology 2007 45 : 277 285.
14. Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996 98 : 1185 1194.
15. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R, Chisari FV. Viral clearance without destruction of infected cells during acute HBV infection. Science 1999 284 : 825 829.
16. Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 1996 2 : 1104 1108.
17. Hollinger FB. Hepatitis B virus infection and transfusion medicine: science and the occult. Transfusion 2008 48 : 1001 1026.
18. Zerbini A, Pilli M, Boni C et al. The characteristics of the cell-mediated immune response identify different profiles of occult hepatitis B virus infection. Gastroenterology 2008 134 : 1470 1481.
19. Blum HE, Galun E, Liang TJ, Vonweizsacker F, Wands JR. Naturally occurring missense mutation in the polymerase gene terminating hepatitis B virus replication. J Virol 1991 65 : 1836 1842.
20. Jeantet D, Chemin I, Mandrand B et al. Cloning and expression of surface antigens from occult chronic hepatitis B virus infections and their recognition by commercial detection assays. J Med Virol 2004 73 : 508 515.
21. Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat 2002 9 : 243 257.
22. Weinberger KM, Bauer T, Bohm S, Jilg WG. High genetic variability of the group-specific a-determinant of hepatitis B virus surface antigen (HBsAg) and the corresponding fragment of the viral polymerase in chronic virus carriers lacking detectable HBsAg in serum. J Gen Virol 2000 81 : 1165 1174.
23. Jardi R, Rodriguez F, Buti M et al. Role of hepatitis B, C, and D viruses in dual and triple infection: influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001 34 : 404 410.
24. Mimms LT, Mosley JW, Hollinger FB et al. Effect of concurrent acute infection with hepatitis C virus on acute hepatitis B virus infection. BMJ 1993 307 : 1095 1097.
25. Pasquinelli C, Shoenberger JM, Chung J et al. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology 1997 25 : 719 727.
26. Bellecave P, Gouttenoire J, Gajer M et al. Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference. Hepatology 2009 50 : 46 55.
27. Chu CJ, Lee SD. Hepatitis B virushepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008 23 : 512 520.
28. Madejon A, Manzano ML, Arocena C, Castillo I, Carreno V. Effects of delayed freezing of liver biopsies on the detection of hepatitis C virus RNA strands. J Hepatol 2000 32 : 1019 1025.
29. Hollinger FB, Lau D T-Y. Hepatitis B: the pathway to recovery through treatment. In : Goodgame R, Graham DY, eds. Gastroenterology Clinics of North America. Philadelphia : Elsevier Saunders Publishers, 2006 : 425 462.
30. Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sang 2001 80 : 63 71.
31. Ronsin C, Pillet A, Bali C, Denoyel GA. Evaluation of the COBAS AmpliPrep-total nucleic acid isolation-COBAS TaqMan hepatitis B virus (HBV) quantitative test and comparison to the VERSANT HBV DNA 3.0 assay. J Clin Microbiol 2006 44 : 1390 1399.
32. Shyamala V, Arcangel P, Cottrell J et al. Assessment of the target-capture PCR hepatitis B virus (HBV) DNA quantitative assay and comparison with commercial HBV DNA quantitative assays. J Clin Microbiol 2004 42 : 5199 5204.
33. Ferguson M, Health A, Lelie N, et al. WHO Working Group on Hepatitis and HIV Diagnostic Kits: Report of a collaborative study to 1) assess the suitability of a candidate replacement International Standard for HBsAg and a reference panel for HBsAg and 2) to calibrate the candidate standard in IU. 2003;WHOBS03.1987, 1-25. Geneva, Switzerland : World Health Organization.
34. Gerlich WH, Glebe D, Schuttler CG. Deficiencies in the standardization and sensitivity of diagnostic tests for hepatitis B virus. J Viral Hepat 2007 14 (Suppl. 1 16 21.
35. Weber B. Diagnostic impact of the genetic variability of the hepatitis B virus surface antigen gene. J Med Virol 2006 78 (Suppl. 1 S59 S65.
36. La'ulu SL, Roberts WL. The analytic sensitivity and mutant detection capability of six hepatitis B surface antigen assays. Am J Clin Pathol 2006 125 : 748 751.
37. Hollinger FB. Hepatitis B virus genetic diversity and its impact on diagnostic assays. J Viral Hepat 2007 14 (Suppl. 1 11 15.
38. Minegishi K, Yoshikawa A, Kishimoto S et al. Superiority of minipool nucleic acid amplification technology for hepatitis B virus over chemiluminescence immunoassay for hepatitis B surface antigen screening. Vox Sang 2003 84 : 287 291.
39. Kuhns MC, Kleinman SH, McNamara AL, Rawal B, Glynn S, Busch MP. Lack of correlation between HBsAg and HBV DNA levels in blood donors who test positive for HBsAg and anti-HBc: implications for future HBV screening policy. Transfusion 2004 44 : 1332 1339.
40. Allain JP. Occult hepatitis B virus infection: implications in transfusion. Vox Sang 2004 86 : 83 91.
41. Wang JT, Sheu JC, Lin JT, Shih LN, Chen DS, Wang TH. Minimal role of hepatitis B virus in posttransfusion non-A, non-B hepatitis in Taiwan: a study by polymerase chain reaction. J Formos Med Assoc 1991 90 : 471 475.
42. Fang Y, Shang QL, Liu JY et al. Prevalence of occult hepatitis B virus infection among hepatopathy patients and healthy people in China. J Infect 2009 58 : 383 388.
43. Kim SM, Lee KS, Park CJ et al. Prevalence of occult HBV infection among subjects with normal serum ALT levels in Korea. J Infect 2007 54 : 185 191.
44. Shih LN, Sheu JC, Wang JT et al. Serum hepatitis B virus DNA in healthy HBsAg-negative Chinese adults evaluated by polymerase chain reaction. J Med Virol 1990 32 : 257 260.
45. Iizuka H, Ohmura K, Ishijima A et al. Correlation between anti-HBc titers and HBV DNA in blood units without detectable HBsAg. Vox Sang 1992 63 : 107 111.
46. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, Paterlini-Brechot P. Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely "occult"? Hepatology 2001 34 : 194 203.
47. Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. Hepatology 2004 39 : 51 57.
48. Minuk GY, Sun DF, Greenberg R et al. Occult hepatitis B virus infection in a North American adult hemodialysis patient population. Hepatology 2004 40 : 1072 1077.
49. Besisik F, Karaca C, Akyuz F et al. Occult HBV infection and YMDD variants in hemodialysis patients with chronic HCV infection. J Hepatol 2003 38 : 506 510.
50. Raimondo G, Pollicino T, Cacciola I, Squadrito G. Occult hepatitis B virus infection. J Hepatol 2007 46 : 160 170.
51. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999 341 : 22 26.
52. Koike K, Kobayashi M, Gondo M, Hayashi I, Osuga T, Takada S. Hepatitis B virus DNA is frequently found in liver biopsy samples from hepatitis C virus-infected chronic hepatitis patients. J Med Virol 1998 54 : 249 255.
53. Castillo I, Rodriguez-Inigo E, Lopez-Alcorocho JM, Bartolome J, Pardo M, Carreno V. Comparative study on the clinical and virological characteristics among patients with single occult hepatitis B virus (HBV), single occult hepatitis C virus (HCV) and occult HBV and HCV dual infection. J Med Virol 2007 79 : 236 241.
54. Marusawa H, Uemoto S, Hijikata M et al. Latent hepatitis B virus infection in healthy individuals with antibodies to hepatitis B core antigen. Hepatology 2000 31 : 488 495.
55. Michalak TI, Pasquinelli C, Guilhot S, Chisari FV. Hepatitis B virus persistence after recovery from acute viral hepatitis. J Clin Invest 1994 93 : 230 239.
56. Coffin CS, Michalak TI. Persistence of infectious hepadnavirus in the offspring of woodchuck mothers recovered from viral hepatitis. J Clin Invest 1999 104 : 203 212.
57. Coffin CS, Pham TNQ, Mulrooney PM, Churchill ND, Michalak TI. Persistence of isolated antibodies to woodchuck hepatitis virus core antigen is indicative of occult infection. Hepatology 2004 40 : 1053 1061.
58. Norman JE, Beebe GW, Hoofnagle JH, Seeff LB. Mortality follow-up of the 1942 epidemic of hepatitis B in the U.S. Army. Hepatology 1993 18 : 790 797.
59. Yuki N, Nagaoka T, Yamashiro M et al. Long-term histologic and virologic outcomes of acute self-limited hepatitis B. Hepatology 2003 37 : 1172 1179.
60. Blackberg J, Kidd-Ljunggren K. Occult hepatitis B virus after acute self-limited infection persisting for 30 years without sequence variation. J Hepatol 2000 33 : 992 997.
61. Aach RD, Alter HJ, Hollinger FB et al. Risk of transfusing blood containing antibody to hepatitis B surface antigen. Lancet 1974 2 : 190 193.
62. Hollinger FB, Dodd RY. Hepatitis B virus traceback and lookback: factors to consider. Transfusion 2009 49 : 176 184.
63. Reesink HW, Engelfriet CP, Henn G et al. Occult hepatitis B infection in blood donors. Vox Sang 2008 94 : 153 166.
64. Kleinman SH, Strong DM, Tegtmeier GG et al. Hepatitis B virus (HBV) DNA screening of blood donations in minipools with the COBAS AmpliScreen HBV test. Transfusion 2005 45 : 1247 1257.
65. Linauts S, Saldanha J, Strong D. PRISM hepatitis B surface antigen detection of hepatitis B virus minipool nucleic acid testing yield samples. Transfusion 2008 48 : 1376 1382.
66. Dreier J, Kroger M, Diekmann J, Gotting C, Kleesiek K. Low-level viraemia of hepatitis B virus in an anti-HBc- and anti-HBs-positive blood donor. Transfus Med 2004 14 : 97 103.
67. Mosley JW, Stevens CE, Aach RD et al. Donor screening for antibody to hepatitis B core antigen and hepatitis B virus infection in transfusion recipients. Transfusion 1995 35 : 5 12.
68. Prince AM, Lee DH, Brotman B. Infectivity of blood from PCR-positive, HBsAg-negative, anti-HBs-positive cases of resolved hepatitis B infection. Transfusion 2001 41 : 329 332.
69. Gerlich WH. Breakthrough of hepatitis B virus escape mutants after vaccination and virus reactivation. J Clin Virol 2006 36 : S18 S22.
70. Satake M, Taira R, Yugi H et al. Infectivity of blood components with low hepatitis B virus DNA levels identified in a lookback program. Transfusion 2007 47 : 1197 1205.
71. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J Hepatol 2009 51 : 798 809.
72. Mason A, Sallie R, Perrillo R et al. Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non-A, non-B fulminant hepatic failure. Hepatology 1996 24 : 1361 1365.
73. Wright TL, Mamish D, Combs C et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet 1992 339 : 952 955.
74. Hytiroglou P, Dash S, Haruna Y et al. Detection of hepatitis B and hepatitis C viral sequences in fulminant hepatic failure of unknown etiology. Am J Clin Pathol 1995 104 : 588 593.
75. Sallie R, Rayner A, Naoumov N, Portmann B, Williams R. Occult HBV in NANB fulminant hepatitis. Lancet 1993 341 : 123.
76. Feray C, Gigou M, Samuel D et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology 1993 104 : 549 555. (Pubitemid 23033429)
77. Teo EK, Ostapowicz G, Hussain M, Lee WM, Fontana RJ, Lok AS. Hepatitis B infection in patients with acute liver failure in the United States. Hepatology 2001 33 : 972 976.
78. Chemin I, Zoulim F, Merle P et al. High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001 34 : 447 454.
79. Berasain C, Betes M, Panizo A et al. Pathological and virological findings in patients with persistent hypertransaminasaemia of unknown aetiology. Gut 2000 47 : 429 435.
80. Squadrito G, Pollicino T, Cacciola I et al. Occult hepatitis B virus infection is associated with the development of hepatocellular carcinoma in chronic hepatitis C patients. Cancer 2006 106 : 1326 1330.
81. Matsuoka S, Nirei K, Tamura A et al. Influence of occult hepatitis B virus coinfection on the incidence of fibrosis and hepatocellular carcinoma in chronic hepatitis C. Intervirology 2008 51 : 352 361.
82. Shetty K, Hussain M, Nei L, Reddy KR, Lok AS. Prevalence and significance of occult hepatitis B in a liver transplant population with chronic hepatitis C. Liver Transpl 2008 14 : 534 540.
83. Mrani S, Chemin I, Menouar K et al. Occult HBV infection may represent a major risk factor of non-response to antiviral therapy of chronic hepatitis C. J Med Virol 2007 79 : 1075 1081.
84. Ikeda M, Kato N. Life style-related diseases of the digestive system: cell culture system for the screening of anti-hepatitis C virus (HCV) reagents: suppression of HCV replication by statins and synergistic action with interferon. J Pharmacol Sci 2007 105 : 145 150.
85. Tamori A, Hayashi T, Shinzaki M et al. Frequent detection of hepatitis B virus DNA in hepatocellular carcinoma of patients with sustained virologic response for hepatitis C virus. J Med Virol 2009 81 : 1009 1014.
86. Stroffolini T, Almasio PL, Persico M et al. Lack of correlation between serum anti-HBcore detectability and hepatocellular carcinoma in patients with HCV-related cirrhosis. Am J Gastroenterol 2008 103 : 1966 1972.
87. Hsia CC, Scudamore CH, Di Bisceglie AM, Tabor E. Molecular and serological aspects of HBsAg-negative hepatitis B virus infections in North America. J Med Virol 2003 70 : 20 26.
88. Uetake S, Yamauchi M, Itoh S, Kawashima O, Takeda K, Ohata M. Analysis of risk factors for hepatocellular carcinoma in patients with HBs antigen- and anti-HCV antibody-negative alcoholic cirrhosis: clinical significance of prior hepatitis B virus infection. Alcohol Clin Exp Res 2003 27 : 47S 51S.
89. Marusawa H, Hijikata M, Chiba T, Shimotohno K. Hepatitis C virus core protein inhibits Fas- and tumor necrosis factor alpha-mediated apoptosis via NF-kappaB activation. J Virol 1999 73 : 4713 4720.
90. Dickson RC, Everhart JE, Lake JR et al. Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. Gastroenterology 1997 113 : 1668 1674.
91. Prieto M, Gomez MD, Berenguer M et al. De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population. Liver Transpl 2001 7 : 51 58.
92. Samuel D, Forns X, Berenguer M et al. Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006). J Hepatol 2006 45 : 127 143.
93. Chazouilleres O, Mamish D, Kim M et al. "Occult" hepatitis B virus as source of infection in liver transplant recipients. Lancet 1994 343 : 142 146.
94. Wachs ME, Amend WJ, Ascher NL et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation 1995 59 : 230 234.
95. Douglas DD, Rakela J, Wright TL, Krom RA, Wiesner RH. The clinical course of transplantation-associated de novo hepatitis B infection in the liver transplant recipient. Liver Transpl Surg 1997 3 : 105 111.
96. Ghisetti V, Marzano A, Zamboni F et al. Occult hepatitis B virus infection in HBsAg negative patients undergoing liver transplantation: clinical significance. Liver Transpl 2004 10 : 356 362.
97. Abdelmalek MF, Pasha TM, Zein NN, Persing DH, Wiesner RH, Douglas DD. Subclinical reactivation of hepatitis B virus in liver transplant recipients with past exposure. Liver Transpl 2003 9 : 1253 1257.
98. Satterthwaite R, Ozgu I, Shidban H et al. Risks of transplanting kidneys from hepatitis B surface antigen-negative, hepatitis B core antibody-positive donors. Transplantation 1997 64 : 432 435.
99. Di Stefano M, Volpe A, Stallone G et al. Occult HBV infection in hemodialysis setting is marked by presence of isolated antibodies to HBcAg and HCV. J Nephrol 2009 22 : 381 386.
100. Kanbay M, Gur G, Akcay A et al. Is hepatitis C virus positivity a contributing factor to occult hepatitis B virus infection in hemodialysis patients? Dig Dis Sci 2006 51 : 1962 1966.
101. Stratta P, Bruschetta E, Minisini R et al. Prevalence and clinical relevance of occult hepatitis B virus infection in patients on the waiting list for kidney transplantation. Transplant Proc 2009 41 : 1132 1137.
102. Peres AA, Dias EA, Chesky M et al. Occult hepatitis B in renal transplant patients. Transpl Infect Dis 2005 7 : 51 56.
103. Hoofnagle JH. Reactivation of hepatitis B. Hepatology 2009 49 : S156 S165.
104. Fukushima N, Mizuta T, Tanaka M et al. Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier. Ann Oncol 2009 20 : 2013 2017.
105. Dhedin N, Douvin C, Kuentz M et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc. Transplantation 1998 66 : 616 619.
106. Hui CK, Cheung WW, Zhang HY et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006 131 : 59 68.
107. Hui CK, Sun H, Au WY et al. Occult hepatitis B virus infection in hematopoietic stem cell donors in a hepatitis B virus endemic area. J Hepatol 2005 42 : 813 819.
108. Ilan Y, Nagler A, Zeira E, Adler R, Slavin S, Shouval D. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients. Bone Marrow Transplant 2000 26 : 633 638.
109. Yeo W, Chan TC, Leung NW et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 2009 27 : 605 611.
110. Onozawa M, Hashino S, Izumiyama K et al. Progressive disappearance of anti-hepatitis B surface antigen antibody and reverse seroconversion after allogeneic hematopoietic stem cell transplantation in patients with previous hepatitis B virus infection. Transplantation 2005 79 : 616 619.
111. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009 50 : 661 662.
112. Foont JA, Schiff ER. Avoid the tragedy of hepatitis B reactivation in immunosuppressed patients. Nat Clin Pract Gastroenterol Hepatol 2007 4 : 128 129.
113. Marzano A, Angelucci E, Andreone P et al. Prophylaxis and treatment of hepatitis B in immunocompromised patients. Dig Liver Dis 2007 39 : 397 408.
114. Mindikoglu AL, Regev A, Schiff ER. Hepatitis B virus reactivation after cytotoxic chemotherapy: the disease and its prevention. Clin Gastroenterol Hepatol 2006 4 : 1076 1081.
115. Morsica G, Ancarani F, Bagaglio S et al. Occult hepatitis B virus infection in a cohort of HIV-positive patients: correlation with hepatitis C virus coinfection, virological and immunological features. Infection 2009 37 : 445 449.
116. Cohen Stuart JW, Velema M, Schuurman R, Boucher CA, Hoepelman AI. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. J Med Virol 2009 81 : 441 445.
117. Firnhaber C, Viana R, Reyneke A et al. Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 2009 13 : 488 492.